Nakashima T, Makishima K, Toriya Y, Murata Y, Watanabe H, Kannae S
Jpn J Antibiot. 1983 Oct;36(10):2733-41.
The clinical effectiveness and safety of cefotiam (CTM) in infectious diseases in the field of otorhinolaryngology was evaluated from 30 patients (otitis media 18, pharyngeal infection 4, chronic paranasal sinusitis 1, esophagitis 1, acute bronchitis 1, others 4). Side effect (fever, nausea) was found in a 14 years old male patient. Skin test revealed positive in 1 patient. These cases were excepted from evaluating clinical effectiveness of CTM. In 28 patients, the overall ratio of clinical effectiveness was 60.7%. In patients of otitis media, the clinical effectiveness ratio was 41.2%, whereas the ratio was 75.0--100% in patients of other diseases. In particular, the clinical effect was fair or poor in patients to whom the drug was given only once a day. These results suggest that this chemotherapeutic drug should be administered at least twice a day, particularly to the patients of otitis media. The bacteriological response to CTM was evaluated from 53 strains, isolated from 28 patients before treatment. Eradication rate of bacteria was 60.4%. No abnormal laboratory findings, relating to the drug, were observed after treatment.
对30例患者（中耳炎18例、咽部感染4例、慢性鼻窦炎1例、食管炎1例、急性支气管炎1例、其他4例）评估了头孢替安（CTM）在耳鼻咽喉科感染性疾病中的临床有效性和安全性。在一名14岁男性患者中发现了副作用（发热、恶心）。1例患者皮肤试验呈阳性。这些病例被排除在CTM临床有效性评估之外。在28例患者中，临床有效性总比例为60.7%。在中耳炎患者中，临床有效性比例为41.2%，而在其他疾病患者中该比例为75.0%-100%。特别是，每天仅给药一次的患者临床效果为中等或较差。这些结果表明，这种化疗药物应至少每天给药两次，尤其是对中耳炎患者。从治疗前28例患者分离出的53株菌株评估了对CTM的细菌学反应。细菌根除率为60.4%。治疗后未观察到与药物相关的异常实验室检查结果。
